Related Experiment Video

Updated: Oct 2, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.9K

Focal adhesion kinase inhibitors, a heavy punch to cancer

Yueling Wu1,2, Ning Li2, Chengfeng Ye1,2

  • 1Department of Obstetrics and Gynecology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524001, China.

Discover Oncology
|February 24, 2022
PubMed

Insights

Focal adhesion kinase (FAK) inhibitors show promise for cancer therapy, particularly in combination strategies to overcome treatment resistance. This review covers FAK inhibitor development, chemotherapy, and future perspectives.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Focal adhesion kinase (FAK) is a key non-receptor tyrosine kinase implicated in cancer progression.
  • Aberrant FAK signaling drives cancer cell growth, adhesion, migration, and tumor microenvironment remodeling.
  • FAK is overexpressed and activated in many cancer types, making it a targetable kinase.

Purpose of the Study:

  • To review the drug development progress of FAK inhibitors.
  • To discuss chemotherapy strategies involving FAK inhibitors.
  • To provide a perspective on the future of FAK inhibitors in cancer therapy.

Main Methods:

  • Literature review of preclinical and clinical studies on FAK inhibitors.
  • Analysis of FAK's role in cancer cell biology and the tumor microenvironment.
  • Synthesis of current chemotherapy and combination strategies.

Main Results:

  • FAK inhibitors have demonstrated promising preclinical and early-stage clinical trial results.
  • Targeting FAK in combination strategies may reverse resistance to existing chemotherapies and targeted therapies.
  • FAK inhibition impacts multiple hallmarks of cancer, including growth, migration, and TME remodeling.

Conclusions:

  • FAK inhibitors represent a promising therapeutic avenue for various cancers.
  • Combination therapies involving FAK inhibitors are crucial for overcoming treatment resistance.
  • Further research into FAK inhibitor development and application is warranted.
Keywords:
Cancer chemotherapyFAK inhibitorsFocal adhesion kinase

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.1K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
2.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K